Table 2.
Univariate and multivariate Cox analysis of DFS.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age, year (>55 vs. ≤55) | 0.965 (0.700–1.330) | 0.827 | – | – |
| Gender (female vs. male) | 1.767 (1.001–3.116) | 0.050 | – | – |
| Cirrhosis (present vs. absent) | 0.987 (0.717–1.359) | 0.934 | – | – |
| PLT, 109/L (>200 vs. ≤200) | 0.666 (0.481–0.922) | 0.014 | – | – |
| ALB, g/L (≤35 vs. >35) | 1.406 (0.838–2.359) | 0.197 | – | – |
| ALP, U/L (>160 vs. ≤160) | 1.050 (0.568–1.939) | 0.876 | – | – |
| ALT, U/L (>40 vs. ≤40) | 1.668 (1.217–2.288) | 0.001 | 1.620 (1.180–2.225) | 0.003 |
| AST, U/L (>40 vs. ≤40) | 1.419 (1.038–1.941) | 0.028 | – | – |
| GGT, U/L (>75 vs. ≤75) | 1.519 (1.104–2.090) | 0.010 | – | – |
| TB, μmol/L (>17.1 vs. ≤17.1) | 1.146 (0.820–1.603) | 0.426 | – | – |
| PT, s (>13 vs. ≤13) | 1.059 (0.708–1.585) | 0.779 | – | – |
| AFP, ng/ml (>200 vs. ≤200) | 1.441 (1.053–1.972) | 0.022 | – | – |
| CA19-9, kU/L (>34 vs. ≤34) | 1.310 (0.925–1.856) | 0.129 | – | – |
| Diameter, cm | 1.132 (1.080–1.187) | <0.001 | – | – |
| Necrosis (present vs. absent) | 2.193 (1.568–3.069) | <0.001 | – | – |
| Capsule (present vs. absent) | 0.413 (0.286–0.598) | <0.001 | 0.504 (0.341–0.745) | <0.001 |
| Margin (non-smooth vs. smooth) | 1.636 (1.196–2.236) | <0.001 | – | – |
| TTPVI (present vs. absent) | 2.368 (1.728–3.245) | <0.001 | 1.842 (1.319–2.572) | <0.001 |
| BCLC (Stage 0 vs. Stage A) | 1.954 (0.915–4.172) | 0.083 | – | – |
AFP, alpha-fetoprotein; AJCC, American Joint Committee on Cancer; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CA19-9, carbohydrate antigen 19-9; DFS, disease-free survival; GGT, gamma-glutamyl transpeptidase; HR, hazard ratio; PLT, platelets; PT, prothrombin time; TB, total bilirubin; TTPVI, two-trait predictor of venous invasion.